Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

about

CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall.

P2860

Q47556581-1DC7E643-1AE7-436C-8A93-6AB7C8B652BA

P2860

Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

Item

http://www.wikidata.org/entity/Q40400859

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prognostic impact of CD5 expre ...... treated with rituximab-EPOCH.

@en

type

Item

label

Prognostic impact of CD5 expre ...... treated with rituximab-EPOCH.

@en

prefLabel

Prognostic impact of CD5 expre ...... treated with rituximab-EPOCH.

@en

P1476

Prognostic impact of CD5 expre ...... s treated with rituximab-EPOCH

@en

P2093

Bei Hu

http://www.w3.org/2001/XMLSchema#string

C Cameron Yin

http://www.w3.org/2001/XMLSchema#string

Guilin Tang

http://www.w3.org/2001/XMLSchema#string

Jie Xu

http://www.w3.org/2001/XMLSchema#string

Joseph D Khoury

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Parth Desai

http://www.w3.org/2001/XMLSchema#string

Pei Lin

http://www.w3.org/2001/XMLSchema#string

Sanam Loghavi

http://www.w3.org/2001/XMLSchema#string

Shaoying Li

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

CD5 expression in human B-cell populations.

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

P304

415-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12847

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Beenu Thakral

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28039906

http://www.w3.org/2001/XMLSchema#string

Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

about

P2860

P2860

Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698